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Abstract: Sodium ion transporters in sarcolemma are involved in numerous vital cell functions, such as excitability, excitationcontraction coupling, energy metabolism, pH and volume regulation, development and growth. In a number of cardiac pathologies, the intracellular sodium concentration ( Preclinical studies showed that pharmacological interventions, targeted against sarcolemmal sodium ion transporters, proved effective in ameliorating heart failure. In this respect: 1) NHE-1 inhibition reduces cardiac remodelling, hypertrophy and HF, although, in the patients following coronary artery bypass graft surgery, it was associated with an increase of stroke.
2) The activity of NBC is up-regulated, during the development of hypertrophy and may be a therapeutic strategy to prevent the development of hypertrophy and HF. 3) NKCC is increased in post-infarction HF, and the inhibition of NKCC attenuated post-infarction remodelling. 4) Inactivation of sodium channels is impaired in HF, which may result, in increased Na + influx and prolongation of the action potential. 5) Blockade of NCX may be useful as a part of a combined therapeutic approach. Inhibition of reversed mode, or activation of forward mode NCX reduce Ca 2+ overload. 6) Inhibition of Na + /K + -ATPase (digoxin), is used to increase contractility, however, it enhances progression of HF. Oppositely, new drugs which increase activity of Na + /K + -ATPase may prevent the development of cardiac remodelling hypertrophy and HF.
In this review we give an overview and discuss the therapeutic relevance of the different sodium ion transport mechanisms in the setting of heart failure.
INTRODUCTION
The incidence and prevalence of heart failure (HF) have increased over the last decades. The main reasons for this increase are the ageing population and an increase in survival rate after myocardial infarction and other cardiovascular diseases. Although, pharmacotherapy has significantly improved survival, the prognosis of HF is still rather poor. Total mortality is high and approximately half of the deaths are sudden and unexpected. Angiotensin-converting-enzyme (ACE)-inhibitors generally given with diuretics, is the standard treatment for patients with HF, whereas, beta-adrenergic receptor antagonists ( -blockers) and Na/K-pump inhibitors (digoxin) are given to respectively prevent arrhythmias and improve contractility. Despite and improvement in the therapy, mortality in heart failure (HF) remains high and there is a need for alternative additional approaches [1, 2] . The major stimulus to initiate HF, is sustained increased workload of the heart, mostly due to the hypertension and/or myocardial infarction. The increased workload leads to hypertrophy and cellular and structural remodelling such as altered calcium handling [3, 4] , excitation-contraction coupling [5] , contractility [6] , energy metabolism [7] , cytoskeleton [8] and extracellular matrix [9] . Dysfunctional Ca 2+ (disturbed Ca 2+ handling) is characterized by reduced systolic Ca 2+ , increased diastolic Ca 2+ , elevated decay time of the Ca 2+ transients, and decreased sarcoplasmic reticulum (SR) Ca 2+ content [10] [11] [12] (see also Fig. 5 ). These alterations translate into functional incompetence of the heart with reduced fractional shortening, increased diastolic tension, relaxation abnormalities and arrhythmias. In addition increased intracellular calcium concentration ([Ca initially an adaptive response, prolonged hypertrophy is associated with increased sudden cardiac death and progression to HF [19] [20] [21] . . In addition, NCX can also function in reversed mode (Ca 2+ influx/Na + efflux) dependent on the sarcolemmal Na + gradient. In animal models of HF and hypertrophy as well as in human heart failure, it has been shown that [Na + ] i is increased [22] [23] [24] [25] [26] [27] [28] [29] [30] . When [Na + ] i increases, NCX shifts to less forward and more reversed mode [22, 23] (see also Fig. 8 ] i rise, may prove beneficial in the patients at risk to develop hypertrophy and HF. In steady state, Na + homeostasis is the result of the balance between the influx and efflux of sodium ions. In cardiac myocytes Na + efflux is primarily regulated by the Na + /K + ATPases with moderate contribution of NCX, whereas Na + influx depends mainly on Na + -channel and NHE-1 activity with minor contribution of other sodium transporters (Fig. 2) . All these mechanisms are subject of regulation [31] and therefore can contribute to abnormal Na + handling in the failing heart. The feature of this review is to discuss the therapeutic relevance of these sodium ion transporters in the treatment of HF. Until now 9 isoforms of the exchanger have been identified [32] . NHE-1 is the most ubiquitously expressed and the predominant isoform in the plasma membrane of the myocardium [33] . The activity of NHE-1 is regulated by e.g., stretch and neurohumoral factors that target membrane bound G-protein coupled receptors, such as catecholamines, angiotensin II and endothelin I. These factors, abundantly present in HF, stimulate their receptors and activate signalling transduction pathways that cause (de)phosphorylation and (un)binding of co-factors from the NHE-1 C-terminus [33] [34] [35] [36] . In animal models and in the patients with HF, NHE-1 activity is proved to be significantly increased [24, 25, [37] [38] [39] [40] [41] (Fig. 3) . It is expected that hyperactivity of NHE-1 is associated with a more alkaline pH i and an elevated [Na + ] i . However, in HF enhanced acid extrusion by NHE-1 is perfectly balanced by an equivalent increase in acid-loading through the Cl -/HCO 3 --exchanger (anion exchanger, AE), thereby leaving pH i unchanged under bicarbonate buffered conditions [42, 43] . Regarding the simultaneous increase in NHE-1 and AE activity at resting pH i values in HF, one can speculates that the actual [Na + ] i under bicarbonate-buffered conditions should be much higher as always measured under non-bicarbonate-buffered conditions (Fig. 4) . Yet, experimental data on this in HF is lacking. Evidence exists that a long term increase in NHE-1 activity is harmful, due to its indirect effect on the [Ca 2+ ] i . Increased NHE-1 activity elevates [Na + ] i ( Fig. 3 ) and subsequently causes a Ca 2+ overload through NCX, which secondary leads to arrhythmias, myocardial dysfunction, hypertrophy, apoptosis and HF [44] [45] [46] [47] [48] . ] i , hypertrophy and the development of HF. In this respect, it has been shown in several studies that chronic inhibition of NHE-1 prevents and/or attenuates hypertrophy and the development of HF [27, 46, [49] [50] [51] [52] [53] [54] [55] [56] . These studies showed that NHE-1 inhibition improves survival rate, reduces fibrosis and apoptosis, preserves contractility, and prevents ionic and electrical remodelling. In accordance, SR calcium handling and the amplitude of calcium transient are normalized in pressure-volume overloaded rabbits with HF, that were fed with a NHE-1 inhibitor "cariporide" containing diet (Fig. 5) . From the prevention of excessive fibrosis, prolongation of action potential duration, and delayed after depolarizations [57] [58] [59] [60] [61] , one can conclude that NHE-1 inhibition is also anti-arrhythmic. This antiarrhythmogenic effect together with maintenance of contractility explains why the rate of survival is higher in HF following inhibition of NHE-1 [46, 49] .
THE
In most studies, in which chronic inhibition of NHE-1 has been applied experimentally, treatment started immediately after the induction of hypertrophy and HF. From a clinical point of view however, it is even more relevant to determine whether chronic inhibition of NHE-1 is capable to reverse signs of hypertrophy and HF, after it has already been developed. Indeed, NHE-1 inhibition treatment reduced hypertrophy in rats with myocardial infarction [50] , and reversed hypertrophy and improved contractility in spontaneously hypertensive rats (SHR) (Fig. 6) [62] . Moreover, in rabbits with volume and pressure overload inhibition of NHE-1, not only reversed hypertrophy and reduced signs of HF but also reversed ionic and electrical remodelling [63] are found.
Unfortunately, in a clinical trial designed to prevent ischemia and reperfusion injury using cariporide to inhibit NHE-1 activation, Fig. (4) . Na + -dependent acid extrusion and Cl --dependent acid loading.
Increased overlap in acid extrusion and acid loading at the resting pHi value increases NaCl loading in HF. A) In healthy hearts, the set-point pHi values, pHi at which an acid-base transporter is quiescent, of NHE and NBC are only slightly more alkaline than the set-point pHi values of CHE and AE. Consequently, the small overlap in Na + -dependent acid extrusion and Cl --dependent acid loading causes a small NaCl influx at the resting pHi. B) In hypertrophied or failing hearts, set-point pHi values of NHE and AE are shifted in the opposite direction probably due to neurohumoral modulation. As a result a large overlap in Na + -dependent acid extrusion and Cl --dependent acid loading occurs which causes an excessive NaCl influx without changing the resting pHi.
in the patients following coronary artery bypass graft surgery, adverse effects were demonstrated [64] . In cariporide treated patients an increase incidence of stroke was found. This halted further clinical studies on NHE-1 inhibitors as a cardio protective drug. More studies are required to find out whether different NHE-1 inhibitors or alternative strategies to inhibit NHE-1 activity will be efficient to treat and prevent the development of hypertrophy and HF in the patients without these adverse effects.
THE Na

+ -HCO 3 -COTRANSPORTER
The Na + -HCO 3 -cotransporter (NBC) is localized in sarcolemma and becomes activated upon intracellular acidosis. NBC transports extracellular Na + and HCO 3 -into the cytoplasm, thereby restoring the acidic pH i to near neutral values. The relative contribution of NHE-1 and NBC in acid load recovery, is approximately 70% and 30%.
Mammalian hearts posses at least two different Na + dependent bicarbonate co-transporters, an electroneutral (1Na:1HCO 3 -) and an electrogenic NBC (1Na:2HCO 3 -) [45] . The human heart NBC (hhNBC) represents the electrogenic NBC (NBCe1) [65] whereas, NBCn1 is the cardiac electroneutral isoform [66] . The only function ascribed to NBC is its role in pH i regulation; however, since it transports Na + into the cytoplasm it may also be important in cardiac Na + and Ca 2+ homeostasis. In addition, activation of the electrogenic hhNBC may also affect the action potential configuration. Although, intracellular proton accumulation is possibly a major stimuli for the activation of NBC, the abundance of modulation sites on NBC also suggests a strong regulation of its activity by several intracellular signalling pathways [45] . Peptide hormones and catecholamines that act on the G-protein coupled receptors modulate NBC by shifting its set-point pH i (pH i at which an acid-base transporter is virtually quiescent) [47] .
There are reports that NBCe1 plays a role in the development of ischemia/reperfusion injury in the heart [65] . Following reperfusion intracellular pH i is quickly restored by NHE-1 and NBC at the expense of Na + influx. 2+ overload at the moment of reperfusion that leads to hypercontracture and lethal cell injury. Indeed, administration of anti-hhNBC antibody markedly protects systolic and diastolic functions of the heart during reperfusion. Yet, the role of NBCn1 in reperfusion injury remains controversial [43] . Recently, it has been shown in a cardiac hypertrophic rat model that the activity of both NBCn1 and NBCe1 are up-regulated [67] . In this rat model, it had been suggested that enhanced NBC activity provides a mechanism for [Na + ] i overload in hypertrophied hearts. In contrast, in a pressure-volume overload rabbit model of HF no differences were observed in cardiac NBC activity [68] The NKCC1 is the most ubiquitous expressed isoform and is present in the heart. It has been demonstrated that NKCC can be modulated by adrenergic, angiotensin II, and aldosterone receptor stimulation [69] . Ligands for these receptors are abundantly present in HF and may increase NKCC activity.
NKCC has been shown to contribute to Na + loading during myocardial ischemia and reperfusion. Accordingly, the NKCC inhibitor bumetanide reduced Na + loading and attenuated ischemic injury in diabetic rats [70] . Moreover, recent evidence indicates that myocardial NKCC is increased in post-infarction HF [71] . Although, in this model of HF, NKCC inhibition attenuated postinfarction remodelling, it remains to be determined whether or not increased NKCC underlies elevated [Na + ] i in HF. If NKCC proves a major pathway for increased Na + influx in HF than classical loop diuretics, bumetanide and furosemide, may be useful therapeutic tool to prevent the development of hypertrophy and HF. It should be taken into account that these loop diuretics reduce volume overload by stimulating natriuresis and diuresis, which by itself, improves hemodynamics and may reduce hypertrophy and HF [72] .
THE LATE Na + -CHANNEL CURRENT
Sodium channels (Na + -channels) are activated on the depolarization of sarcolemma. The Na + current (I Na ) flowing through these channels, is responsible for the fast upstroke of the cardiac action potential (AP) and contributes to the fast conduction during cardiac excitation. Most of the current rapidly inactivates (I NaT ) within a few milliseconds upon depolarization, however, a small fraction of this current inactivates slowly, the so-called late sodium current (I NaL ) [73] (Fig. 7 panel A) . The TTX-resistant Na + -channel Na(v)1.5 is predominantly expressed in the heart, whereas the minor part of the sodium channel is composed of the TTX-sensitive sodium channels Na(v)1.1, 1.2, 1.3, 1.4, 1.6 [74] . Electrophysiological recordings showed that TTX-resistant and TTX-sensitive Na + channels, respectively, accounted for 92% and 8% of the I Na , in adult ventricular cardiomyocytes [75] . The gating and kinetics of the sodium channel are largely controlled by the membrane voltage, however the channels can also be regulated by PKA and PKC [76] , calcium, calmodulin and CaMKII [77] .
Initial studies using whole-cell patch-clamp technique configuration, showed no change in I NaT in HF [78] , although later studies showed a decrease in current density [79, 80] . In this respect, it must be realized that reduction of I NaT can lead to slowing of the upstroke of the AP, reduced conduction velocity, unidirectional block and re-entrant arrhythmias [80] . However, the amount of Na + influx will not be changed unless the amplitude of the upstroke of the AP is changed. Similar amplitude of the upstroke, fast or slow, requires an equal amount of Na + entry albeit in a longer period of time. Therefore, reduction of I NaT will not necessarily change [Na + ] i . In several studies it has been shown that I NaL is increased in HF [81] [82] [83] [84] . In contrast to I NaT an increase of I NaL results in prolongation of the AP duration (Fig. 7 panel B) and increased influx of Na + ions. For that reason it has been suggested that increased [Na + ] i in HF is caused by an increase of I NaL and that inhibition of I NaL can prevent [Ca 2+ ] i overload and may be beneficial for the development of hypertrophy and HF [83, 85, 86 ]. Yet, no data are available in which inhibition of I NaL proved beneficial in preventing the development of hypertrophy and HF or in reducing [Na + ] i . On the other hand, it has been shown that inhibition of I NaL can shorten AP duration and decrease the propensity to evoke EADs related arrhythmias (Fig. 7 panel C) [82] [83] [84] [85] [86] and improve mechanical efficiency [87] . Whether I NaL inhibition will be an effective treatment for hypertrophy and HF remains to be investigated.
THE Na
+ /Ca
2+ -EXCHANGER
The Na + /Ca 2+ -exchanger (NCX), a surface membrane antiporter, is the primary pathway for Ca 2+ efflux. The driving force of NCX depends on the sarcolemmal Na + and Ca 2+ gradient and the membrane potential. NCX catalyzes the electrogenic transport of one Ca 2+ ion across the membrane in exchange for three Na + ions in a reversible manner, depending on its direction. By convention NCXmediated transport is called 'forward' when Na + is transported inward and Ca 2+ outward and 'reversed', when ions are transported in the opposite directions.
The cardiac specific isoform NCX1 is abundantly present in the sarcolemma of cardiac myocytes. The large cytoplasmic loop of NCX is believed to contain the regulatory sites of the protein. Regulation is achieved by a variety of extracellular and intracellular factors. However, the exact mechanisms are not completely understood and require further investigation [31, [88] [89] [90] .
In hypertrophy and HF it has been shown that NCX expression, activity and driving force is altered [23, 24, [91] [92] [93] [94] [95] [96] [97] and therefore could play a role in the impairment of Ca 2+ and Na + handling, altered contractility and arrhythmogenesis [88, [98] [99] [100] . It has to be realized, because of the steady-state consideration, that NCXmediated Ca 2+ efflux is equal to the L-type calcium channel mediated Ca 2+ influx. L-type calcium current in HF proved unchanged or even reduced [101] [102] [103] [104] [105] [106] [107] . Thus regarding steady-state consideration, the Ca 2+ and Na + flux through NCX in HF is most likely not different from the 'normal' and thus cannot contribute to enhanced Na + influx and altered Na + handling observed in HF. On the other hand, it is known that the driving force of NCX is shifted to less forward mode, and increased reversed mode largely caused by an increase of [Na + ] i [23, 24] (Fig. 8) . This results in an increase of cytosolic Ca 2+ [24] , to compensate for the shift in driving force, until the Ca 2+ efflux through NCX equals the Ca 2+ influx.
KB-R7943 and SEA-0400 are inhibitors of NCX [89, 107] . KB-R7943 largely affects the reverse mode of NCX [107] , whereas SEA-0400 has no preference for forward or reversed mode. Inhibition of the forward mode reduces Ca 2+ efflux and increases [Ca 2+ ] i , which may ultimately activate hypertrophic signalling pathways (Fig. 1) and ] i overload, which could reduce activation of the hypertrophic response and DADs related arrhythmias. Indeed, recent studies have provided evidence that inhibition of reversed mode by KB-R7943 is effective in reducing cytosolic Ca 2+ overload, cell injury and arrhythmias in different kinds of preparation and experimental conditions. [107, 108] . Few data are available regarding HF. In failing myocytes it has been shown that inhibition of NCX improves excitation-contraction coupling in HF [109] . So, therapeutic intervention, which inhibits reversed mode or activates forward mode NCX might reduce Ca 2+ overload in HF and as a consequence reduce the hypertrophic response and DADs related arrhythmias. In addition, the regulatory mechanisms of the NCX protein, which are achieved by a variety of extracellular and intracellular factors, are in principle therapeutic targets to influence the activity of NCX.
THE Na
+ /K + -ATPase
The Na + /K + -ATPase (Na/K-pump) is found at the plasma membrane and provides the major route for cellular Na + extrusion [110, 111] . The energy derived from the hydrolysis of ATP is used by the Na/K-pump to extrude three Na + ions for two K + ions. A principal modulator of Na/K-pump activity is [Na + ] i [112] [113] [114] . In this way the Na/K-pump keeps [Na + ] i low and [K + ] i high, thereby maintaining the asymmetric gradients of these ions across the sarcolemma.
The myocardium expresses three Na/K-pump -subunit isoforms ( 1, 2, and 3) and one ß1-subunit isoform. The -subunits differ in affinity for intracellular Na + and for the inhibitor ouabain. In addition, also a Na/K-pump regulatory -subunit, phospholemman (PLM), is expressed in the heart.
Modulation of the Na/K-pump activity can be achieved by changing expression levels, shifting the -isoform expression, and changing PLM phosphorylation. PLM phosphorylation by protein kinase A (PKA) and protein kinase C (PKC), causes dissociation of PLM from the -subunits thereby increasing the Na + and K + affinity of the Na/K-pump [115] . Further, it should be realized that the sodium gradient across the sarcolemma largely depends on the energy that can be transferred to the Na/K-pump by hydrolysis of ATP ( G ATP ) [116] . A rather small change of ±2 kJ/mole of the G ATP will shift the thermodynamic equilibrium of the Na/K-pump and consequently, a 1.5 mM higher [Na + ] i . In rabbit failing myocytes it has been shown that G ATP was ±2 kJ/mole lower compared to control myocytes [25] .
Several studies have reported a decrease in the activity of the Na/K-pump in hypertrophy and HF due to downregulation of the number of pumps and/or due to shift in isoform expression [117] [118] [119] [120] [121] [122] [123] [124] [125] . However, most studies regarding expression of the Na/Kpump were performed in tissue homogenates and could reflect changes in non-myocytes [126] . In addition, these experiments cannot dis-criminate between sarcolemma and intercellular Na/Kpump expression. It is therefore hard to show a clear relationship between the expression and activity of Na/K-pump. In this respect it is surprising that there are only a few reports in which Na/K-pump function activity is actually measured in the setting of HF. In myocytes from rats with HF, the maximal Na + efflux rate was reduced with unchanged [Na + ] i -affinity [127] . In contrast, in myocytes from dogs with hypertrophy induced by chronic atrioventricular block, maximal Na/K-pump activity is unchanged but [Na + ] iaffinity was reduced [28] . In myocytes from rabbits, with volume and pressure overload induced HF, neither maximal Na + efflux rate nor the affinity of Na/K-pump was reduced [23] . So, it seems that Na/K-pump expression may be altered in cardiac myocytes without a change in maximal activity. Moreover, from steady-state considerations it follows that the Na/K-pump in HF, even if downregulated at the protein level, is capable to balance increased sodium influx. Thus, the actual activity of Na/K-pump must be higher in HF. Increased [Na + ] i in HF could kinetically compensate for downregulation of the Na/K-pump and increased sodium influx in order to achieve steady-state. Another reason for the discrepancy between the expressions and activity of the Na/K-pump might be altered regulation of the pump in HF. However, signalling cascades involved in hormonal regulation, in particular, are varied and complex. Alterations in regulation may be the result of posttranslational modification such as phosphorylation. It remains to be determined whether and to what extent such modifications affect the Na/Kpump, per se, or some regulatory component [128, 129] . ] i , development of hypertrophy and HF and prevent the remodelling. Whether Na/K-pump activation will be an effective treatment for hypertrophy and HF remains to be investigated and needs development of new drugs. Until now inhibition of the Na/K-pump (digoxin) is used to increase contractility of the heart in the setting of HF. Inhibition of the pump results in a further increase of [Na + ] i and secondarily to an increase of [Ca 2+ ] i and contractility. Although, the short term effect of Na/K-pump inhibition is beneficial in the treatment of HF because of increased contractility. ] i , which is known to be a hypertrophic signal. Cardiac hypertrophy is a major risk factor for cardiac death and commonly precedes the development of HF. The altered Na + and Ca 2+ handling in HF leads to electrical remodelling and increased incidence of EADs and DADs, which are known triggers for arrhythmias. In this respect, it has been shown experimentally that normalizing Na + and/or Ca 2+ handling is beneficial in the prevention and regression of hypertrophy and HF and related arrhythmias. These findings may help to find new therapeutic strategies for the treatment of cardiac hypertrophy and HF.
